Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant.